Compare Inovio Pharmaceuticals Inc (INO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Oatly Group AB - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Oatly Group AB - ADR trades at $9.41 (market cap $308.50M). The key difference: Oatly Group AB - ADR is far larger — about 3.5× Inovio Pharmaceuticals Inc's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | OTLY | |
|---|---|---|
Market Cap | $89.27M | $308.50M |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $18.54 |
52-Week Low | $1.05 | $8.03 |
Enterprise Value | $60.28M | $806.12M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
OTLY trades at $9.81, down 2.29% on the day, with a bullish technical signal from moving averages. Revenue grew to $862.46M in 2025, but net losses persist at -$152.77M. Cash burn remains a concern with negative operating cash flow of -$23.72M. The company announced Q2 2026 results for July 22, 2026, and continues brand partnerships like the Nespresso iced coffee collaboration.
Outlook is mixed: strong brand and revenue growth offer potential, but profitability challenges and high debt-to-asset ratio of 66.53% pose significant risks. Analyst consensus is divided with 44% buy ratings, yet cash runway constraints highlighted by Seeking Alpha on 2026-05-14 require careful monitoring for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
